SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT01237522

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

A Pharmacokinetic Evaluation of Metformin in Relation to the Polymorphism A270S in Healthy Caucasian Volunteers.

The aim of the study is to evaluate the pharmacokinetics of metformin in healthy Caucasians volunteers with and without the polymorphism A270S in OCT2,thus the study hypothesis is that renal clearance of metformin is affected in Caucasian with the known single nucleotide polymorphisms A270S in OCT2.

NCT01237522 Metformin Organic Cation Transporter 2 Polymorphism,Single Nucleotide

1 Interventions

Name: Metformin

Description: A single dose study with one tablet of metformin 500 mg, time frame 24 hours
Type: Drug
Group Labels: 2

Homo- or heterozygote for A270S minor alleles Homozygote for the A270S wildetype

Primary Outcomes

Measure: Renal clearance of metformin

Time: 24 Hours
Purpose: Health Services Research

Allocation: Non-Randomized

Parallel Assignment

There is one SNP

SNPs

1 rs316019

Inclusion Criteria: - Healthy volunteers - Written consent - rs316019 genotyped - Age 18-65 years old Exclusion Criteria: - Daily medication - Alcohol abuse - Pregnancy - Breastfeeding Inclusion Criteria: - Healthy volunteers - Written consent - rs316019 genotyped - Age 18-65 years old Exclusion Criteria: - Daily medication - Alcohol abuse - Pregnancy - Breastfeeding Metformin Organic Cation Transporter 2 Polymorphism,Single Nucleotide null


HPO Nodes